IAP20 Rec'd FOT/770 31 JAN 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Ryouichi HOSHINO et al.

Mail Stop: PCT

Serial No. NEW

Attorney Docket No. 2006-0019A

Filed January 31, 2006

ORAL SUSTAINED-RELEASE TABLET [Corresponding to PCT/JP2004/011067

Filed August 3, 2004]

THE COMMISSIONER IS AUTHORIZED TO CHARGE ANY DEFICIENCY IN THE FEE FOR THIS PAPER TO DEPOSIT ACCOUNT NO. 23-0975.

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed.

1a. [X] This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

| 1b. | [] This Information Disclosure Statement is submitted |
|-----|---|
| | after the events of above paragraph 1a and prior to the mailing date of a final |

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) [] the certification of paragraph 2 below is provided, or
- (2) [] the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.
- 1c. [] This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified

- a. [] that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
- b. [] that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.
- 3. [] Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

- 4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
 - a. [] a full or partial English language translation submitted herewith,
 - b. [X] a foreign patent office search report (International Search Report) (in the English language) submitted herewith,
 - c. [X] the concise explanation contained in the specification of the present application at pages 1-2,
 - d. [X] the concise explanation set forth in the attached English language abstract,
 - e. [] the concise explanation set forth below or on a separate sheet attached to the reference:
- 5. [X] A foreign patent office search report (International Search Report) citing one or more of the references is enclosed.

Respectfully submitted,

Ryouichi HOSHINO et al.

Moland P Davi

Registration No. 25,134 Attorney for Applicants

MRD/pth Washington, D.C. 20006-1021 Telephone (202) 721-8200 Facsimile (202) 721-8250 January 31, 2006

| Sheet 1 of 1 | <i>b</i> * | · · · · · · · · · · · · · · · · · · · | INFORMA | TION DISCLO | SURE STATEMEN | 7 to 21 | FIICE (| aturie it | 131 JA | <u>M 200</u> | |
|---|--|---------------------------------------|----------------|-----------------------------------|-------------------------|----------|----------|----------------------------------|--|--------------|--|
| FORM PTO 1449 (<i>m</i> | ATTY DOCKET NO. 2006-0019A SERIAL NO. NEW | | | | | | - | | | | |
| U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) | | | | APPLICANT Ryouichi HOSHINO et al. | | | | | | | |
| LIST OF | FILING DATE GROUP | | | | | | | | | | |
| Date Submitted to PTO: January 31, 2006 | | | | | January 31, 2006 | | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | | NAME CL | | LASS | SUBCLASS FILING DAT APPROPRIA | | | |
| | AA | | | | | | | | | : | |
| | АВ | | | | | | | | | | |
| | AC | | | | | | | | | | |
| | AD | | | | | | | | | | |
| | AE | | | | | | | | | | |
| | AF | | | | | | | | | | |
| | AG | | | | | | | | | | |
| | АН | | | | | | | | en e | | |
| * * | . Al | | | | | | | | | | |
| | | | FORE | EIGN PATENT | DOCUMENTS | | | | * * | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | | С | LASS | SUBCLASS | TRANSLATION YES NO | | |
| | AJ | 01/34147 | 5/2001 | | wo | | | | | | |
| | AK | 01/76557 | 10/2001 | WO | | | | | | | |
| | AL | 10-67657 | 3/1998 | | Japan | | | | | | |
| | АМ | | | | | | | | | | |
| | AN | | | | | | | | | | |
| | | OTHER | DOCUMENT(S) (/ | ncluding Autho | or, Title, Date, Pertin | ent Page | s, Etc.) | · | <u> </u> | | |
| | AO Hiroyuki Miyachi et al., "Synthesis and Antimuscarinic Activity of a Series of 4-(1-Imidazolyl)-2, 2-diphenylbutyramides: Discovery of Potent and Subtype-selective Antimuscarinic Agents", Bioorganic & Medicinal Chemistry, 7, pages 1151-1161, 1999. | | | | | | | | | | |
| | AP | | | | | | | | | | |
| | AQ | | | | | | | | | | |
| | | | | | | | | | | | |
| EXAMINER | | | | | DATE CONSIDERED | | | | | | |